Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.59 |
| ▸ | CTSS | P25774 | 4/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 2/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842588 | 1.00 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL14338698 | 1.00 | CTSK (0.59) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL7729227 | 0.95 | CTSK (0.55) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL7375068 | 0.95 | CTSK (0.55) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL13198524 | 0.92 | ATM (0.55) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL7375856 | 0.91 | CTSK (0.51) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL25842742 | 0.89 | CTSK (0.54) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL21715604 | 0.88 | CTSK (0.56) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL18653949 | 0.88 | CTSK (0.58) | CTSKCTSSATMSYKCTSL | |
| SCHEMBL4727222 | 0.88 | CTSK (0.58) | CTSKCTSSATMSYKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-01-14 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584714-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-02-21 | — | — | US | disclosed |
| US-7309721-B2 | Immunosuppressants for treating diseases and conditions of bone marrow, organ and tissue transplant rejection; chemotherapeutic drug for cancers; antiinflammatory agents for rheumatoid arthritis; activate the production of lymphocyte; 2-Amino-4-(4-(octylphenyl))butanol, O-phosphate | MERCK + CO., INC. (US) | 2007-12-18 | — | — | US | disclosed |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | DOHERTY GEORGE A | 2007-09-27 | — | — | US | disclosed |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | DOHERTY GEORGE A | 2007-09-27 | — | — | US | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2002012184-A1 | PROCESS FOR PREPARING ALPHA-AMINO ACIDS AND THEIR DERIVATIVES INCLUDING PHENYLALANINE AND HOMOPHENYLALANINE AND THEIR INTERMEDIATES | CHEMBIONEX CO., LTD. (KR) | 2002-02-14 | — | — | WO | disclosed |
| CN-1243505-A | Benzamidine derivatives | AJINOMOTO KK (JP) | 2000-02-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584714-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CTSK 485/4885CTSS 439/4885ATM 1956/4885 |
| US-20230145071-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CTSK 485/4885CTSS 439/4885ATM 1956/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CTSK 485/4885CTSS 439/4885ATM 1956/4885 |
| US-12195427-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | CTSK 485/4885CTSS 439/4885ATM 1956/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CTSK 436/4885CTSS 379/4885ATM 2049/4885 |
| US-20070224263-A1 | Aminoalkylphosphonates and related compounds as Edg receptor agonists | ADGRE5, EDNRA, ADGRF1 | CTSK 2374/4885CTSS 2395/4885ATM 1614/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | CTSK 485/4885CTSS 439/4885ATM 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.